Abstract Phospholipases A 2 (PLA 2 s) are important enzymes for the metabolism of fatty acids in membrane phospholipids. Among the three major classes of PLA 2 s in the mammalian system, the group IV calcium-dependent cytosolic PLA 2 alpha (cPLA 2 α) has received the most attention because it is widely expressed in nearly all mammalian cells and its active participation in cell metabolism. Besides Ca 2+ binding to its C2 domain, this enzyme can undergo a number of cell-specific post-translational modifications, including phosphorylation by protein kinases, S-nitrosylation through interaction with nitric oxide (NO), as well as interaction with other proteins and lipid molecules. Hydrolysis of phospholipids by cPLA 2 yields two important lipid mediators, arachidonic acid (AA) and lysophospholipids. While AA is known to serve as a substrate for cyclooxygenases and lipoxygenases, which are enzymes for the synthesis of eicosanoids and leukotrienes, lysophospholipids are known to possess detergent-like properties capable of altering microdomains of cell membranes. An important feature of cPLA 2 is its link to cell surface receptors that stimulate signaling pathways associated with activation of protein kinases and production of reactive oxygen species (ROS). In the central nervous system (CNS), cPLA 2 activation has been implicated in neuronal excitation, synaptic secretion, apoptosis, cell-cell interaction, cognitive and behavioral function, oxidative-nitrosative stress, and inflammatory responses that underline the pathogenesis of a number of neurodegenerative diseases. However, the types of extracellular agonists that target intracellular signaling pathways leading to cPLA 2 activation among different cell types and under different physiological and pathological conditions have not been investigated in detail. In this review, special emphasis is given to metabolic events linking cPLA 2 to activation in neurons, astrocytes, microglial cells, and cerebrovascular cells. Understanding the molecular mechanism(s) for regulation of this enzyme is deemed important in the development of new therapeutic targets for the treatment and prevention of neurodegenerative diseases.
Introduction
Fatty acids are essential components of phospholipids and are integral parts of cell membranes. Four decades ago, Dr. Nicolas Bazan made the novel observation that fatty acids in the brain undergo rapid release upon excitation due to electroconvulsive shock and cerebral ischemia [1, 2] . This observation, later regarded as the "Bazan effect," has attracted extensive interest for neuroscientists to search for the underlying biochemical mechanism(s) for fatty acid release from membrane phospholipids. Subsequent studies led to evidence that fatty acids in membrane phospholipids undergo dynamic turnover through an "acylation-deacylation" mechanism mediated by phospholipases A 2 (PLA 2 s) and ATP-dependent acyl-coenzyme A: lysophospholipid acyltransferases. It is further recognized that this acylation-deacylation process provides an important mechanism for the release of selective fatty acids in different types of membrane phospholipids upon special demand.
Phospholipids in the central nervous system (CNS) are enriched with polyunsaturated fatty acids (PUFAs), and PLA 2 s are the key enzymes for hydrolysis of the PUFAs in the sn-2 position of the glycerol moiety. More than 20 isoforms of PLA 2 s are present in mammalian cells, and they are roughly divided into three major categories, namely secretory (sPLA 2 ), calcium-independent (iPLA 2 ), and calciumdependent (cPLA 2 ). In recent years, there are increasing interests to uncover the role of different PLA 2 s in regulating cell functions under physiological and pathological conditions [3] [4] [5] [6] . Arachidonic acid (AA) and docosahexaenoic acid (DHA) are two important PUFAs offering unique physiological functions to the brain. While the release of AA has been linked to the action of cPLA 2 , the PLA 2 for release of DHA is less clear, although the action of iPLA 2 has been suggested [7, 8] . AA is a substrate for cyclooxygenases and lipoxygenases and serves as the precursor for the synthesis of eicosanoids and prostanoids that mediate a wide variety of inflammatory responses [9] . On the other hand, DHA is effective in mediating anti-inflammatory and neuroprotective responses [8] and is the precursor for the biosynthesis of neuroprotectin D (NPD1) and resolvins [9] [10] [11] [12] [13] [14] . An important goal here is to provide a comprehensive review of the extracellular agonists and receptor signaling pathways regulating cPLA 2 activity and/or expression in different cell types in the CNS.
The calcium-dependent group IV cytosolic PLA 2 (cPLA 2 α) is a 97-kDa protein constitutively expressed in nearly all brain cells. Investigation on cPLA 2 has gained special attention lately not only because of its requirement for calcium binding in the C2 domain, but this molecule can also undergo a number of post-translational modifications through phosphorylation and S-nitrosylation. In particular, several active serine/threonine residues are susceptible to phosphorylation by protein kinases that are involved in important signaling pathways, e.g., ERK1/2 and p38 MAPK at Ser505, Mnk1 at Ser727, and CaMKII at Ser515 [15] . In human epithelial cells, S-nitrosylation by nitric oxide (NO) of an active cysteine residue can enhance cPLA 2 activity by several folds [16] . cPLA 2 also contains cationic domains for binding zwitterionic lipids such as phosphatidylinositol 4,5-bisphosphate (PIP 2 ) [5] , ceramide-1-phosphate (C1P), and lactosylceramide [5, 17, 18] . These properties suggest active modulation of cPLA 2 through interactions with lipids and intracellular signaling molecules.
In the CNS, cPLA 2 activation has been implicated in the pathogenesis of a number of neurodegenerative diseases, including experimental autoimmune encephalomyelitis [19, 20] , Alzheimer's disease [21] [22] [23] [24] [25] [26] , Niemann-Pick disease [27] , tumorigenesis [28] , stroke [29] [30] [31] , alcoholism [32, 33] , as well as a number of affective disorders [34] . However, few studies have elucidated the extracellular agonists and signaling pathways leading to cPLA 2 activation in these disease conditions.
Role of cPLA 2 in Neuronal Excitation and Synaptic Plasticity
Neuronal stimulation by ionotropic glutamate receptor agonists, such as N-methyl-D-aspartic acid (NMDA), is known to elicit a massive and rapid influx of Ca 2+ and leading to activation of Ca 2+ -dependent enzymes, mitochondrial dysfunction, and neuronal apoptosis. Activation of the NMDA receptor is also marked by a rapid production of reactive oxygen species (ROS) which is attributed to activation of NADPH oxidase [35, 36] . Studies in our laboratory further linked NMDA-induced ROS production with activation of the MEK1/2-ERK1/2 pathway and phosphorylation of cPLA 2 [35] . These findings demonstrated activation of cPLA 2 together with neuronal excitation and oxidative stress. In primary cultures of cortical and hippocampal neurons, treatment with a PLA 2 inhibitor, methyl arachidonyl fluorophosphonate (MAFP), resulted in altered neuronal morphology and reduced neurite outgrowth and viability [37] . Stereotaxic injection of the PLA 2 inhibitor to the hippocampal CA1 area also caused a reduction of neuronal membrane fluidity which is thought to contribute to impairment in memory function [38] .
In the peripheral nervous system, cPLA 2 is implicated in the injury of primary sensory neurons and pain behavior (tactile allodynia) [39] . The increase in cPLA 2 activity is attributed to the stimulation of the ionotropic P2X receptors and subsequent activation of MAPK and CaMKII [40] . In fact, phosphorylation of cPLA 2 by CaMKII was also observed in vascular smooth muscle cells following stimulation by norepinephrine. Under this condition, phosphorylation of cPLA 2 by CaMKII (at S515) occurred prior to the phosphorylation by ERK1/2 (at S505), and complete phosphorylation by both kinases were required for AA release [41] . There is further evidence that upon stimulation by norepinephrine, CaMKII promoted translocation of cPLA 2 from the cytosol to the nuclear envelope [42] . In fact, cPLA 2 and CaMKII appeared to be present in close proximity to the dorsal root ganglion cells, and stimulation of the ganglion cells with ATP promoted the translocation of p-cPLA 2 to the plasma membrane [40] . Since CaMKII is regarded an important protein kinase in modulation of synaptic plasticity and long-term potentiation [43] , these studies presented a possible link between CaMKII and cPLA 2 in modulating neuronal activities under disease conditions.
Organization of the pre-and post-synaptic structures is extremely complex. The presence of cPLA 2 in the synaptic area suggests a possible role for this enzyme in regulating synaptic activity. There is evidence for cPLA 2 to modulate vesicle formation, for promoting neurite outgrowth and maintenance of growth cone activity. In the dorsal root ganglion, semaphorin 3A (a class of secreted and membrane protein) can trigger a signaling pathway involving cPLA 2 activation, AA release, and synthesis of 12(S)-hydroxyeicosatetraenoic acid (12(S)HETE) and, in turn, mediates neuronal growth cone activity [44] . In agreement with the role of cPLA 2 in neuronal membrane and synaptic activity, hippocampal neurons isolated from cPLA 2 knockout (KO) mice showed measurable differences in the nuclei and soma volume and the structure of the synaptic cleft as compared with neurons from wild-type animals [45] . In the hippocampus and cerebellum, the PKC-ERK1/2-cPLA 2 pathway has also been implicated in long-term synaptic plasticity and regulation of AMPA receptor trafficking [46] .
Albeit at lower levels as compared to stimulation by NMDA, oligomeric amyloid-beta peptide (Aβ) can also stimulate ROS production in neurons and subsequently phosphorylate ERK1/2 and cPLA 2 [35] . However, prolonged exposure of neurons to Aβ led to a decrease in NMDA response and an increase in mitochondrial dysfunction [47] . Studies by Kriem's group demonstrated the ability for Aβ to activate cPLA 2 and subsequently mitochondrial dysfunction and neuronal apoptosis [21, 48] . Besides stimulation of phospho-cPLA 2 , Aβ exposure also led to activation of neutral sphingomyelinase and ceramide and, together, neuronal apoptosis [49] . Mitigation of ROS production in neurons, such as that using gp91ds-tat, a specific inhibitor for the gp91phox subunit of NADPH oxidase, could protect neurons from the deleterious effects of Aβ [47] . Studies with cPLA 2 -deficient mice, as well as with different experimental models and pharmacological agents, have also demonstrated the critical role for cPLA 2 in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and stroke [50] [51] [52] [53] [54] [55] . These studies further underscore the role of cPLA 2 in neuronal metabolic signaling pathways linking to Ca 2+ homeostasis, protein kinase activation, and oxidative-nitrosative stress.
cPLA 2 in Oxidative and Inflammatory Signaling Pathways in Astrocytes
Our earlier studies with astrocytes demonstrated the ability for ATP/UTP to stimulate G protein-coupled P2Y 2 receptor and signaling pathways leading to activation of PKC-dependent and PKC-independent phosphorylation of ERK1/2 and cPLA 2 [56] . Besides ATP, phorbol ester (PMA) can also increase in phospho-cPLA 2 , AA release, and production of prostaglandin E2 (PGE2) in astrocytes [57] . This last study further demonstrated a priming effect for pro-inflammatory cytokines (such as TNF-α, IL-1β, and IFN-γ) to enhance the production of PGE2 following short-term exposure to ATP and PMA [57] . Other agents such as lipopolysaccharides (LPS) can stimulate cPLA2 and PGE2 production through an ERK1/2-dependent pathway in astrocytes [58] . In fact, a number of other stimuli, including ammonia [59] , alcohol [60] , ceramide [61] , bradykinin [62, 63] , and diethylmaleate/ iodoacetate [64] , have been shown to stimulate cPLA 2 and engage in astrocytic inflammatory and oxidative pathways.
Aggregated Aβ can also confer cytotoxic effects to astrocytes. Using specific inhibitors for cPLA 2 and iPLA 2 , the study by Zhu et al. demonstrated the ability for Aβ to incur a time-difference activation of cPLA 2 and iPLA 2 in alteration of mitochondrial membrane depolarization [65] . Oligomeric Aβ (1-42) increased phosphorylation of cPLA 2 in astrocytes through activating the NADPH oxidase and MAPK pathways, and subsequently, this led to perturbation of mitochondrial function, impairment in ATP production, and increase in oxidative stress. Menadione, a redox-active compound capable of inducing intracellular ROS production in astrocytes, was shown to stimulate cPLA 2 through p38 MAPK and ERK1/2, subsequently leading to an increase in actin polymerization and cytoskeletal protrusions [66] . Astrocyte plasma membranes became more molecularly ordered due to oxidative stress induced by menadione [66] . Downregulation of cPLA 2 , either with a pharmacological inhibitor or by RNA interference, could abrogate the menadione-induced morphological changes in astrocytes. These studies suggest an important role for ROS in activation of astrocytes and signaling pathways involving cPLA 2 to elicit biochemical, morphological, and biophysical changes reminiscent of reactive astrocytes in pathological conditions. cPLA 2 2 and PGE2 production through a signal transduction pathway involving sphingomyelinase and p38 MAPK [67] . ATP can also induce cPLA 2 and PGE2 release from microglial cells, and this action is attributed to the activation of P2X7 receptors [68] . However, PGE2 production due to stimulation of P2X7 receptors appeared to involve COX-1 and not COX-2. In another study, infection of macrophage with Candida albicans resulted in rapid activation of cPLA 2 , AA release, and production of eicosanoids, and the production of PGE2 was also mediated through COX-1 [69] . Since COX-1 is constitutive as compared to COX-2 which is induced through the nuclear factor-kappa B (NF-κB) pathway, these studies demonstrate that rapid response of cPLA2 to agonists can produce inflammatory events without involvement of the transcriptional processes. Chronic infusion of LPS to brains has been shown to cause inflammatory responses with increases in TNF-α, inducible NO synthase (iNOS), and microglial activation [70] . Under this condition, the increase in cPLA 2 and production of 5-LOX was attributed to the action of COX-2.
Studies from our laboratory have demonstrated the involvement of ERK1/2 in LPS-IFN-γ-induced production of NO and ROS in microglial cells [71, 72] . In agreement with results from a study by Ribeiro et al., our study also indicated an increase in phospho-cPLA 2 following LPS-IFN-γ treatment (Chuang, unpublished data) [73] . A study with rat primary microglial cells further showed an increase in the expression of total cPLA 2 at 6-8 h after treatment with LPS [74] . In the BV-2 microglial cells, LPS-induced cPLA 2 activation was mediated by ERK1/2 and JNK but not p38 MAPK [73] . Furthermore, cPLA 2 small interfering RNA (siRNA) or its inhibitor, AACOCF3, attenuated LPS-induced NO and ROS production as well as iNOS and p67phox expression in microglial cells [73, 74] . Taken together, these studies demonstrated the critical role of cPLA 2 in mediating inflammatory responses in microglial cells.
Superoxide anions generated by NADPH oxidase can react with NO to form peroxinitrite (ONOO-), a highly toxic radical with a potent ability to damage cell membranes. Oxidation to PUFAs in membrane phospholipids can produce 4-hydroxy-2-nonenal (4-HNE), another reactive lipid peroxidation product which can form protein adducts [75] and thus is used as a good marker for assessing oxidative stress in brain tissue and brain injury [36] . In a study with the Ra2 murine microglial cells, 4-HNE was shown to upregulate cPLA 2 expression as well as increased phosphorylation through a pathway involving ERK1/2 and p38 MAPK [75] .
Similar to neurons and astrocytes, aggregated Aβ can also confer toxic effects on microglial cells, as demonstrated by increased production of ROS and upregulation of phosphocPLA 2 expression and cPLA 2 activity [76] . Antisense cPLA 2 and pyrrophenone, a cPLA 2 -specific inhibitor, were effective in abolishing ROS, iNOS, and PGE2 production induced by Aβ.
IFN-γ, or type II interferon, is a cytokine critical for innate and adaptive immunity against viral and bacterial infections and in autoinflammatory and autoimmune diseases. Although IFN-γ is produced predominantly by natural killer T cells and lymphocytes, microglial cells are capable of responding to this cytokine, which is known to stimulate the canonical Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway for producing transcription factors such as interferon gamma-activated sites (GAS) and IFN regulatory factors (IRF). In microglial cells, activation of GAS is necessary for induction of the iNOS gene by IFN-γ and LPS [77] . In our study with immortalized microglial cells (BV-2 and HAPI), IFN-γ can not only activate the canonical JAK-STAT pathway but also induce a noncanonical pathway involving Raf-Ras and MEK1/2, which, in turn, lead to activation of ERK1/2 [72] as well as cPLA 2 (Chuang, unpublished data). Indeed, IFN-γ-induced stimulation of p-ERK1/2 has become a key signaling pathway for activation of a number of cytoplasmic proteins, including NADPH oxidase subunits for ROS production, filopodia formation, and IKKα for the NF-κB pathway in these microglial cells (Fig. 1) .
Spinal microglial cells are activated during spinal cord injury and have been implicated in the pathogenesis of neuropathic pain [78] . Spinal microglial cells are susceptible to stimulation by LPS which induces the increase in COX-1 and COX-2 and production of PGE2 and NO through the p38 MAPK pathway [79] . Interestingly, a recent study indicated a role for lysophosphatidic acid (LPA) for microglial stimulation upon spinal cord injury and neuropathic pain [80] . In addition, this study further demonstrated that NMDA and neurokinin 1 receptors, cPLA 2 , iPLA 2 , and microglial activation, as well as LPA1 and LPA3 receptors, were all involved in nerve injury-induced LPA production and neuropathic pain [81] . Obviously, more studies are needed to investigate the underlying mechanisms linking spinal microglial cells and neurons in neuropathic pain.
cPLA 2 and Signaling Pathways in Cerebrovascular Cells
The brain's microvascular structure is a multicellular complex composed of endothelial cells, astrocytes, and pericytes, and together, these cells are responsible for many biological processes such as regulation of the blood-brain barrier (BBB), angiogenesis, transmigration of monocytes, and atherogenesis. Previous studies have shown that activation of the PKC-ERK1/2-cPLA 2 pathway is important in endothelial functions [82] . Similar to astrocytes, cPLA 2 phosphorylation/activation in cerebral endothelial cells is regulated by oxidative signaling through NADPH oxidase and ERK1/2 [83] . Vascular endothelial growth factor (VEGF) is important in endothelial angiogenesis and is responsible for cell growth, migration, and tubulogenesis in endothelial cells. VEGF receptors are coupled to the downstream signaling pathway involving activation of Src-PLD1-PKCγ and, in turn, stimulation of cPLA 2 [84] . The important role of cPLA 2 in mediating VEGFinduced DNA synthesis, migration, and tube formation in human retinal microvascular endothelial cells was further supported by depleting cPLA 2 with siRNA [84] .
Gram-negative pathogens, such as Escherichia coli, can invade brain microvascular endothelial cells and cross the BBB, and this type of infection can be a major cause of neonatal meningitis [82] . PLA 2 and their metabolites have been implicated in mediating communication between endothelial cells and pericytes through signaling pathways involving PKCα and MAPK/ERK [85, 86] . In a study with human brain microvascular endothelial cells, cPLA 2 , AA release, and synthesis of cysteinyl leukotrienes (LTs) were induced upon an invasion of Group B Streptococcus, a pathogen important in the development of neonatal meningitis [87] . Cronobacter sakazakii, another opportunistic pathogen that targets endothelial cells, is involved in neonatal sepsis and meningitis through activation of the PI3K/Akt and cPLA 2 signaling Fig. 1 A graphical illustration depicting the role of cPLA2 in oxidative and inflammatory signaling pathways in microglial cells. This figure demonstrates the multiple signaling pathways leading to phosphorylation of ERK1/2 and cPLA2 and the multiple links for ERK1/2 to other metabolic processes including phosphorylation of NADPH oxidase subunits leading to production of ROS and development of filopodia pathway leading to disruption of actin microfilaments [88] . The important role of cPLA 2 in C. sakazakii-induced Akt signaling and actin rearrangement can be demonstrated by treating cells with the cPLA 2 inhibitor AACOCF3.
Results of these studies well demonstrated the important role of cPLA 2 in mediating damaging effects induced by pro-inflammatory pathogens.
Targeting cPLA 2 
and Upstream Signaling Pathways to Mitigate Neurodegenerative Processes
Increased oxidative stress and chronic inflammation are common factors associated with many age-related neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and stroke. In a cerebral ischemia model induced by middle cerebral artery occlusion (MCAO) in mice, a transient and rapid increase in total and phosphorylated cPLA 2 expression was observed in the ischemic hemisphere immediately after MCAO and returned to control levels by 2 h after reperfusion [55] . The early increase in cPLA 2 expression was coupled to the increase in COX-2, oxidative stress, and upregulation of phospho-p38 and pERK1/2 MAPK [55] . In another study using the MCAO model in rats, increases in expressions of phospho-p38 MAPK and phospho-cPLA 2 were observed 6 h and 3 days, respectively, after ischemia/ reperfusion [89] . Under this condition, administration of the p38 MAPK inhibitor SB203580 could suppress phosphocPLA 2 activation and attenuate BBB extravasation and subsequent induction of edema due to ischemia/reperfusion. AACOCF3, a cPLA 2 inhibitor, is also effective in reducing ischemia-induced infarction [90] . Recent studies also suggest effective application of AACOCF3 to ameliorate injuries in animal models of other neurodegenerative diseases, including experimental autoimmune encephalomyelitis [74] .
There is increasing evidence supporting the use of botanical antioxidants to suppress oxidative and inflammatory pathways in different cell types in the CNS. A recent comprehensive review outlined the mechanisms of actions of a number of flavonoids found in cocoa, tea, berries, and citrus to mitigate multiple age-associated events including impaired cognition and neuro-inflammation [91] . As an example, the leaf extract of Centella asiatica, used as an alternative medicine for memory improvement in the Indian Ayurvedic system, was shown to inhibit cPLA 2 and sPLA 2 activities in primary cortical neurons [92] . Another study with Ginkgo biloba extract (EGb761) showed the contribution of cPLA 2 and ERK1/2 to the signaling pathway to protect spinal cord neurons from glutamate excitotoxicity [93] . Although our studies did not include the analysis of cPLA 2 , we demonstrated the ability of EGCG from green tea [47] and honokiol, a polyphenol from Magnolia bark, to inhibit NMDA-induced neuronal excitation and ROS production from primary cortical neurons [72] .
Buddleja officinalis extract, a traditional Korean herbal medicine used to treat strokes, headaches, vascular diseases, and neurological disorders, was shown to exert anti-inflammatory effects (LPS-induced iNOS) by suppressing the ERK1/2 and NF-κB pathways [94] . Wogonin, an active component from the root of the Chinese herbal plant Huang qin, was shown to attenuate endotoxin/IFN-γ-induced PGE2 and NO production in microglial cells through the Src-ERK1/2-NF-κB pathway, albeit the exact involvement of cPLA 2 remains to be further demonstrated [95] .
Conclusions and Perspectives
Taken together, these studies suggest involvement of cPLA 2 in oxidative and inflammatory signaling pathways and provide evidence for its link to multiple cell-specific receptors and agonists in the CNS. These characteristic properties of cPLA 2 underscore its role in regulating cell metabolism under different physiological and pathological conditions. Studies here also highlight an important link between cPLA 2 and MAPKs, especially ERK1/2 and p38 MAPK in different cell types. Recognizing this metabolic link is important because these kinases are involved in phosphorylation of many other cellular proteins, including phosphorylation of NADPH oxidase subunits required for ROS production [96] . In both neurons and microglial cells, signaling pathways leading to ERK1/2, ROS, and cPLA 2 activation have been shown to explain neuronal excitotoxicity as well as glial oxidative and inflammatory responses [35, 71] . Our studies with microglial cells further place ERK1/2 and cPLA 2 in a cross-talk mechanism between NF-κB and JAK-STAT pathways induced by LPS and IFN-γ, respectively (Fig. 1) . Since other types of PLA 2 are present in these cells, future studies should be directed to understanding the relationship between cPLA 2 and other PLA 2 s, in particular iPLA 2 and sPLA 2 , in mediating inflammatory responses.
